Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK

Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Theranostics 2020-01, Vol.10 (17), p.7710-7729
Hauptverfasser: Hu, Xiong-Ke, Rao, Shan-Shan, Tan, Yi-Juan, Yin, Hao, Luo, Ming-Jie, Wang, Zhen-Xing, Zhou, Jin-Hua, Hong, Chun-Gu, Luo, Zhong-Wei, Du, Wei, Wu, Ben, Yan, Zi-Qi, He, Ze-Hui, Liu, Zheng-Zhao, Cao, Jia, Wang, Yang, Situ, Wei-Yi, Liu, Hao-Ming, Huang, Jie, Wang, Yi-Yi, Xia, Kun, Qian, Yu-Xuan, Zhang, Yan, Yue, Tao, Liu, Yi-Wei, Zhang, Hong-Qi, Tang, Si-Yuan, Chen, Chun-Yuan, Xie, Hui
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7729
container_issue 17
container_start_page 7710
container_title Theranostics
container_volume 10
creator Hu, Xiong-Ke
Rao, Shan-Shan
Tan, Yi-Juan
Yin, Hao
Luo, Ming-Jie
Wang, Zhen-Xing
Zhou, Jin-Hua
Hong, Chun-Gu
Luo, Zhong-Wei
Du, Wei
Wu, Ben
Yan, Zi-Qi
He, Ze-Hui
Liu, Zheng-Zhao
Cao, Jia
Wang, Yang
Situ, Wei-Yi
Liu, Hao-Ming
Huang, Jie
Wang, Yi-Yi
Xia, Kun
Qian, Yu-Xuan
Zhang, Yan
Yue, Tao
Liu, Yi-Wei
Zhang, Hong-Qi
Tang, Si-Yuan
Chen, Chun-Yuan
Xie, Hui
description Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects. A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis. The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK). Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.
doi_str_mv 10.7150/thno.45858
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7359101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2598248418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-1d9de0651ab6fd945e0e06563d310564c76040054844b974606477df23966563</originalsourceid><addsrcrecordid>eNpVUV1r3iAYldGxlne96Q8YQu8K6TRRk9wMSru2Y4WOtfdiokksiU-q5h3vv9pPnOkXnTzw-ODxnKMHoSNKTkvKydc4ODhlvOLVB3RAq6LKSsHI3rv9PjoM4YGkxUhe0_oT2i9yUXFC-QH6e-mXNkIwWQsqGo3PXB-ihwkHO26Nx9YNtrExYAjRQFC-hUnh3sOfOGDlNJ5MVCGVDXhrFZ7TXYjW9fj37V2mzWycNi5iNcOcdBIqDh6WfkjdYDVG41W04DB0uB-XNll5omxgtGHCze7VwUr56-LnZ_SxU2Mwhy99g-4vv9-fX2c3t1c_zs9uspYRETOqa22I4FQ1otM144asoyh0QQkXrC1F-g7CWcVYU5dMEMHKUnd5UYsVtkHfnmnnpZmMbtMTvBrl7O2k_E6CsvL_E2cH2cNWlgWvKaGJ4PiFwMPjYkKUD7B4lyzLnNdVnoRTQht08oxqPYTgTfemQIlc85VrvvIp3wT-8t7TG_Q1zeIfJAWlpg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598248418</pqid></control><display><type>article</type><title>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Hu, Xiong-Ke ; Rao, Shan-Shan ; Tan, Yi-Juan ; Yin, Hao ; Luo, Ming-Jie ; Wang, Zhen-Xing ; Zhou, Jin-Hua ; Hong, Chun-Gu ; Luo, Zhong-Wei ; Du, Wei ; Wu, Ben ; Yan, Zi-Qi ; He, Ze-Hui ; Liu, Zheng-Zhao ; Cao, Jia ; Wang, Yang ; Situ, Wei-Yi ; Liu, Hao-Ming ; Huang, Jie ; Wang, Yi-Yi ; Xia, Kun ; Qian, Yu-Xuan ; Zhang, Yan ; Yue, Tao ; Liu, Yi-Wei ; Zhang, Hong-Qi ; Tang, Si-Yuan ; Chen, Chun-Yuan ; Xie, Hui</creator><creatorcontrib>Hu, Xiong-Ke ; Rao, Shan-Shan ; Tan, Yi-Juan ; Yin, Hao ; Luo, Ming-Jie ; Wang, Zhen-Xing ; Zhou, Jin-Hua ; Hong, Chun-Gu ; Luo, Zhong-Wei ; Du, Wei ; Wu, Ben ; Yan, Zi-Qi ; He, Ze-Hui ; Liu, Zheng-Zhao ; Cao, Jia ; Wang, Yang ; Situ, Wei-Yi ; Liu, Hao-Ming ; Huang, Jie ; Wang, Yi-Yi ; Xia, Kun ; Qian, Yu-Xuan ; Zhang, Yan ; Yue, Tao ; Liu, Yi-Wei ; Zhang, Hong-Qi ; Tang, Si-Yuan ; Chen, Chun-Yuan ; Xie, Hui</creatorcontrib><description>Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects. A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis. The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK). Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.</description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.45858</identifier><identifier>PMID: 32685015</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Adolescent ; Animals ; Apoptosis ; Apoptosis - drug effects ; Aqueous solutions ; Bone cancer ; Bone Neoplasms - drug therapy ; Bone Neoplasms - pathology ; Cancer therapies ; Carbon ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Chemotherapy ; Cisplatin - administration &amp; dosage ; Dehydrogenases ; Efficiency ; Female ; Fructose - chemistry ; Glucose ; Humans ; Infant ; Infant, Newborn ; Injections, Intravenous ; Kinases ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - secondary ; Male ; Metabolism ; Metal Nanoparticles - administration &amp; dosage ; Metal Nanoparticles - chemistry ; Metastasis ; Mice ; Mitochondria - drug effects ; Mitochondria - metabolism ; Osteosarcoma - drug therapy ; Osteosarcoma - secondary ; Oxidation-Reduction - drug effects ; Pancreatic cancer ; Pharmacokinetics ; Primary Cell Culture ; Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists &amp; inhibitors ; Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism ; Reactive oxygen species ; Reactive Oxygen Species - metabolism ; Renal Elimination ; Research Paper ; Sarcoma ; Signal Transduction - drug effects ; Silver - administration &amp; dosage ; Silver - pharmacokinetics ; Silver - urine ; Tissue Distribution ; Tumors ; Warburg Effect, Oncologic - drug effects ; Xenograft Model Antitumor Assays ; Young Adult</subject><ispartof>Theranostics, 2020-01, Vol.10 (17), p.7710-7729</ispartof><rights>The author(s).</rights><rights>2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-1d9de0651ab6fd945e0e06563d310564c76040054844b974606477df23966563</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359101/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359101/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32685015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Xiong-Ke</creatorcontrib><creatorcontrib>Rao, Shan-Shan</creatorcontrib><creatorcontrib>Tan, Yi-Juan</creatorcontrib><creatorcontrib>Yin, Hao</creatorcontrib><creatorcontrib>Luo, Ming-Jie</creatorcontrib><creatorcontrib>Wang, Zhen-Xing</creatorcontrib><creatorcontrib>Zhou, Jin-Hua</creatorcontrib><creatorcontrib>Hong, Chun-Gu</creatorcontrib><creatorcontrib>Luo, Zhong-Wei</creatorcontrib><creatorcontrib>Du, Wei</creatorcontrib><creatorcontrib>Wu, Ben</creatorcontrib><creatorcontrib>Yan, Zi-Qi</creatorcontrib><creatorcontrib>He, Ze-Hui</creatorcontrib><creatorcontrib>Liu, Zheng-Zhao</creatorcontrib><creatorcontrib>Cao, Jia</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><creatorcontrib>Situ, Wei-Yi</creatorcontrib><creatorcontrib>Liu, Hao-Ming</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Wang, Yi-Yi</creatorcontrib><creatorcontrib>Xia, Kun</creatorcontrib><creatorcontrib>Qian, Yu-Xuan</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Yue, Tao</creatorcontrib><creatorcontrib>Liu, Yi-Wei</creatorcontrib><creatorcontrib>Zhang, Hong-Qi</creatorcontrib><creatorcontrib>Tang, Si-Yuan</creatorcontrib><creatorcontrib>Chen, Chun-Yuan</creatorcontrib><creatorcontrib>Xie, Hui</creatorcontrib><title>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</title><title>Theranostics</title><addtitle>Theranostics</addtitle><description>Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects. A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis. The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK). Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.</description><subject>Adolescent</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Aqueous solutions</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Carbon</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration &amp; dosage</subject><subject>Dehydrogenases</subject><subject>Efficiency</subject><subject>Female</subject><subject>Fructose - chemistry</subject><subject>Glucose</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Injections, Intravenous</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - secondary</subject><subject>Male</subject><subject>Metabolism</subject><subject>Metal Nanoparticles - administration &amp; dosage</subject><subject>Metal Nanoparticles - chemistry</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - secondary</subject><subject>Oxidation-Reduction - drug effects</subject><subject>Pancreatic cancer</subject><subject>Pharmacokinetics</subject><subject>Primary Cell Culture</subject><subject>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists &amp; inhibitors</subject><subject>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism</subject><subject>Reactive oxygen species</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Renal Elimination</subject><subject>Research Paper</subject><subject>Sarcoma</subject><subject>Signal Transduction - drug effects</subject><subject>Silver - administration &amp; dosage</subject><subject>Silver - pharmacokinetics</subject><subject>Silver - urine</subject><subject>Tissue Distribution</subject><subject>Tumors</subject><subject>Warburg Effect, Oncologic - drug effects</subject><subject>Xenograft Model Antitumor Assays</subject><subject>Young Adult</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVUV1r3iAYldGxlne96Q8YQu8K6TRRk9wMSru2Y4WOtfdiokksiU-q5h3vv9pPnOkXnTzw-ODxnKMHoSNKTkvKydc4ODhlvOLVB3RAq6LKSsHI3rv9PjoM4YGkxUhe0_oT2i9yUXFC-QH6e-mXNkIwWQsqGo3PXB-ihwkHO26Nx9YNtrExYAjRQFC-hUnh3sOfOGDlNJ5MVCGVDXhrFZ7TXYjW9fj37V2mzWycNi5iNcOcdBIqDh6WfkjdYDVG41W04DB0uB-XNll5omxgtGHCze7VwUr56-LnZ_SxU2Mwhy99g-4vv9-fX2c3t1c_zs9uspYRETOqa22I4FQ1otM144asoyh0QQkXrC1F-g7CWcVYU5dMEMHKUnd5UYsVtkHfnmnnpZmMbtMTvBrl7O2k_E6CsvL_E2cH2cNWlgWvKaGJ4PiFwMPjYkKUD7B4lyzLnNdVnoRTQht08oxqPYTgTfemQIlc85VrvvIp3wT-8t7TG_Q1zeIfJAWlpg</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Hu, Xiong-Ke</creator><creator>Rao, Shan-Shan</creator><creator>Tan, Yi-Juan</creator><creator>Yin, Hao</creator><creator>Luo, Ming-Jie</creator><creator>Wang, Zhen-Xing</creator><creator>Zhou, Jin-Hua</creator><creator>Hong, Chun-Gu</creator><creator>Luo, Zhong-Wei</creator><creator>Du, Wei</creator><creator>Wu, Ben</creator><creator>Yan, Zi-Qi</creator><creator>He, Ze-Hui</creator><creator>Liu, Zheng-Zhao</creator><creator>Cao, Jia</creator><creator>Wang, Yang</creator><creator>Situ, Wei-Yi</creator><creator>Liu, Hao-Ming</creator><creator>Huang, Jie</creator><creator>Wang, Yi-Yi</creator><creator>Xia, Kun</creator><creator>Qian, Yu-Xuan</creator><creator>Zhang, Yan</creator><creator>Yue, Tao</creator><creator>Liu, Yi-Wei</creator><creator>Zhang, Hong-Qi</creator><creator>Tang, Si-Yuan</creator><creator>Chen, Chun-Yuan</creator><creator>Xie, Hui</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</title><author>Hu, Xiong-Ke ; Rao, Shan-Shan ; Tan, Yi-Juan ; Yin, Hao ; Luo, Ming-Jie ; Wang, Zhen-Xing ; Zhou, Jin-Hua ; Hong, Chun-Gu ; Luo, Zhong-Wei ; Du, Wei ; Wu, Ben ; Yan, Zi-Qi ; He, Ze-Hui ; Liu, Zheng-Zhao ; Cao, Jia ; Wang, Yang ; Situ, Wei-Yi ; Liu, Hao-Ming ; Huang, Jie ; Wang, Yi-Yi ; Xia, Kun ; Qian, Yu-Xuan ; Zhang, Yan ; Yue, Tao ; Liu, Yi-Wei ; Zhang, Hong-Qi ; Tang, Si-Yuan ; Chen, Chun-Yuan ; Xie, Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-1d9de0651ab6fd945e0e06563d310564c76040054844b974606477df23966563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Aqueous solutions</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Carbon</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration &amp; dosage</topic><topic>Dehydrogenases</topic><topic>Efficiency</topic><topic>Female</topic><topic>Fructose - chemistry</topic><topic>Glucose</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Injections, Intravenous</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - secondary</topic><topic>Male</topic><topic>Metabolism</topic><topic>Metal Nanoparticles - administration &amp; dosage</topic><topic>Metal Nanoparticles - chemistry</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - secondary</topic><topic>Oxidation-Reduction - drug effects</topic><topic>Pancreatic cancer</topic><topic>Pharmacokinetics</topic><topic>Primary Cell Culture</topic><topic>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists &amp; inhibitors</topic><topic>Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism</topic><topic>Reactive oxygen species</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Renal Elimination</topic><topic>Research Paper</topic><topic>Sarcoma</topic><topic>Signal Transduction - drug effects</topic><topic>Silver - administration &amp; dosage</topic><topic>Silver - pharmacokinetics</topic><topic>Silver - urine</topic><topic>Tissue Distribution</topic><topic>Tumors</topic><topic>Warburg Effect, Oncologic - drug effects</topic><topic>Xenograft Model Antitumor Assays</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Xiong-Ke</creatorcontrib><creatorcontrib>Rao, Shan-Shan</creatorcontrib><creatorcontrib>Tan, Yi-Juan</creatorcontrib><creatorcontrib>Yin, Hao</creatorcontrib><creatorcontrib>Luo, Ming-Jie</creatorcontrib><creatorcontrib>Wang, Zhen-Xing</creatorcontrib><creatorcontrib>Zhou, Jin-Hua</creatorcontrib><creatorcontrib>Hong, Chun-Gu</creatorcontrib><creatorcontrib>Luo, Zhong-Wei</creatorcontrib><creatorcontrib>Du, Wei</creatorcontrib><creatorcontrib>Wu, Ben</creatorcontrib><creatorcontrib>Yan, Zi-Qi</creatorcontrib><creatorcontrib>He, Ze-Hui</creatorcontrib><creatorcontrib>Liu, Zheng-Zhao</creatorcontrib><creatorcontrib>Cao, Jia</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><creatorcontrib>Situ, Wei-Yi</creatorcontrib><creatorcontrib>Liu, Hao-Ming</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Wang, Yi-Yi</creatorcontrib><creatorcontrib>Xia, Kun</creatorcontrib><creatorcontrib>Qian, Yu-Xuan</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Yue, Tao</creatorcontrib><creatorcontrib>Liu, Yi-Wei</creatorcontrib><creatorcontrib>Zhang, Hong-Qi</creatorcontrib><creatorcontrib>Tang, Si-Yuan</creatorcontrib><creatorcontrib>Chen, Chun-Yuan</creatorcontrib><creatorcontrib>Xie, Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Xiong-Ke</au><au>Rao, Shan-Shan</au><au>Tan, Yi-Juan</au><au>Yin, Hao</au><au>Luo, Ming-Jie</au><au>Wang, Zhen-Xing</au><au>Zhou, Jin-Hua</au><au>Hong, Chun-Gu</au><au>Luo, Zhong-Wei</au><au>Du, Wei</au><au>Wu, Ben</au><au>Yan, Zi-Qi</au><au>He, Ze-Hui</au><au>Liu, Zheng-Zhao</au><au>Cao, Jia</au><au>Wang, Yang</au><au>Situ, Wei-Yi</au><au>Liu, Hao-Ming</au><au>Huang, Jie</au><au>Wang, Yi-Yi</au><au>Xia, Kun</au><au>Qian, Yu-Xuan</au><au>Zhang, Yan</au><au>Yue, Tao</au><au>Liu, Yi-Wei</au><au>Zhang, Hong-Qi</au><au>Tang, Si-Yuan</au><au>Chen, Chun-Yuan</au><au>Xie, Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK</atitle><jtitle>Theranostics</jtitle><addtitle>Theranostics</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>10</volume><issue>17</issue><spage>7710</spage><epage>7729</epage><pages>7710-7729</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><abstract>Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Ångstrom-scale silver particles (AgÅPs) and determined the anti-tumor efficacy of fructose-coated AgÅPs (F-AgÅPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgÅPs and aimed to assess whether F-AgÅPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgÅPs-induced anti-osteosarcoma effects. A modified method was developed to prepare smaller F-AgÅPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgÅPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgÅPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgÅPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgÅPs-induced apoptosis. The newly obtained F-AgÅPs (9.38 ± 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgÅPs were excreted through feces. F-AgÅPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK). Our study suggests the promising prospect of F-AgÅPs as a powerful selective anticancer agent for osteosarcoma therapy.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>32685015</pmid><doi>10.7150/thno.45858</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1838-7640
ispartof Theranostics, 2020-01, Vol.10 (17), p.7710-7729
issn 1838-7640
1838-7640
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7359101
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Adolescent
Animals
Apoptosis
Apoptosis - drug effects
Aqueous solutions
Bone cancer
Bone Neoplasms - drug therapy
Bone Neoplasms - pathology
Cancer therapies
Carbon
Cell Line, Tumor
Cell Proliferation - drug effects
Chemotherapy
Cisplatin - administration & dosage
Dehydrogenases
Efficiency
Female
Fructose - chemistry
Glucose
Humans
Infant
Infant, Newborn
Injections, Intravenous
Kinases
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Male
Metabolism
Metal Nanoparticles - administration & dosage
Metal Nanoparticles - chemistry
Metastasis
Mice
Mitochondria - drug effects
Mitochondria - metabolism
Osteosarcoma - drug therapy
Osteosarcoma - secondary
Oxidation-Reduction - drug effects
Pancreatic cancer
Pharmacokinetics
Primary Cell Culture
Pyruvate Dehydrogenase Acetyl-Transferring Kinase - antagonists & inhibitors
Pyruvate Dehydrogenase Acetyl-Transferring Kinase - metabolism
Reactive oxygen species
Reactive Oxygen Species - metabolism
Renal Elimination
Research Paper
Sarcoma
Signal Transduction - drug effects
Silver - administration & dosage
Silver - pharmacokinetics
Silver - urine
Tissue Distribution
Tumors
Warburg Effect, Oncologic - drug effects
Xenograft Model Antitumor Assays
Young Adult
title Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A54%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fructose-coated%20Angstrom%20silver%20inhibits%20osteosarcoma%20growth%20and%20metastasis%20via%20promoting%20ROS-dependent%20apoptosis%20through%20the%20alteration%20of%20glucose%20metabolism%20by%20inhibiting%20PDK&rft.jtitle=Theranostics&rft.au=Hu,%20Xiong-Ke&rft.date=2020-01-01&rft.volume=10&rft.issue=17&rft.spage=7710&rft.epage=7729&rft.pages=7710-7729&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.45858&rft_dat=%3Cproquest_pubme%3E2598248418%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598248418&rft_id=info:pmid/32685015&rfr_iscdi=true